Equities Analysts Set Expectations for Harrow Q1 Earnings

Harrow, Inc. (NASDAQ:HROW - Free Report) - Equities researchers at B. Riley reduced their Q1 2025 earnings per share estimates for shares of Harrow in a research note issued on Monday, March 31st. B. Riley analyst M. Mamtani now expects that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.15. B. Riley has a "Buy" rating and a $65.00 price objective on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. B. Riley also issued estimates for Harrow's FY2025 earnings at $0.78 EPS, FY2026 earnings at $2.67 EPS and FY2027 earnings at $4.79 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The business had revenue of $66.83 million during the quarter, compared to analysts' expectations of $66.01 million.

Separately, HC Wainwright restated a "buy" rating and set a $57.00 price target on shares of Harrow in a research note on Monday, March 31st.

Harrow Stock Down 2.2 %

NASDAQ HROW traded down $0.54 on Thursday, reaching $23.52. The company had a trading volume of 520,963 shares, compared to its average volume of 504,940. Harrow has a 52-week low of $9.86 and a 52-week high of $59.23. The stock has a market capitalization of $838.58 million, a P/E ratio of -25.02 and a beta of 0.46. The company's fifty day moving average is $27.98 and its 200 day moving average is $37.36. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Remove Ads

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of Harrow by 195.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock valued at $11,313,000 after acquiring an additional 166,602 shares during the last quarter. FMR LLC grew its holdings in Harrow by 521.6% during the 3rd quarter. FMR LLC now owns 11,034 shares of the company's stock valued at $496,000 after buying an additional 9,259 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Harrow by 3,015.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 79,974 shares of the company's stock worth $3,596,000 after buying an additional 77,407 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Harrow during the third quarter valued at approximately $338,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Harrow during the third quarter worth $1,469,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.